NDC product
imatinib mesylate
NDC 0832-0533 · Upsher-Smith Laboratories, LLC
Key facts
| Product NDC | 0832-0533 |
|---|---|
| Proprietary name | imatinib mesylate |
| Nonproprietary name | imatinib mesylate |
| Substances | IMATINIB MESYLATE |
| Dosage form | TABLET |
| Route | ORAL |
| Labeler | Upsher-Smith Laboratories, LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA212135 |
| Pharmacologic classes | Bcr-Abl Tyrosine Kinase Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Kinase Inhibitor [EPC] |
| Marketing start | May 17, 2024 |
| Marketing end | Jan 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory